Vnitr Lek 2020, 66(1):e4-e10 | DOI: 10.36290/vnl.2020.026

Prevalence and risk factors of T-cell mediated rejection in patients after liver transplantation from deceased donors: a retrospective study over 10 years

Svetlana Adamcová-Selčanová1, Ľubomír Skladaný1, Tomáš Koller2
1 HEGITO (Division Hepatology, gastroenterology and liver transplantation) of Department Internal medicine II, Faculty of Medicine, Slovak Medical University, FD Roosevelt Hospital, Banská Bystrica, Slovakia
2 5 th Department Internal Medicine, Comenius University Faculty of Medicine, University Hospital Bratislava Ruzinov, Bratislava, Slovakia

Introduction: T-cell mediated rejection (TCMR) is still one of the most common non-surgical complications following liver transplantation (LTx).

Aims: To determine the prevalence, risk factors and outcome of TCMR after LTx from deceased donors (DDLT) in a single center.

Methods: Retrospective analysis; Study interval: May 2008-December 2017. Inclusion criteria: DDLT at this TC; exclusion criteria: patients treated with CyA or basiliximab. Recorded variables: demographics, MELD score, Child-Pugh, etiology, CIT (Cold Ischemia Time), BG (blood groups), tacrolimus (TAC) on 5th day post LTx and at discharge, length of hospital stay (LOS), survival. TCMR was defined histologically, liver biopsy was performed only in patients having an increase in liver function tests or unexplained liver dysfunction.

Results: 193 patients were included, median age was 53.6, 41.3 % were females, median MELD score 16.0; Child-Pugh score 10. TCMR was diagnosed in 21 patients (11.4 %). The comparison between groups (TCMR and no-TCMR) showed the following differences: age: 54.3 vs 42.3 years (p = 0.073); etiology of autoimmune hepatitis (AIH) 33.3 vs 6.7 %, (p = 0.001), PSC (Primary Sclerosing Cholangitis) 19.0 vs 6.7 %, (p = 0.13). We observed no significant differences among other etiologies, CIT and BG. Level of TAC on the 5th day post LTx was 5.90 [4.00-9.30] vs 4.80 [2.60-7.00] ng/ml (p = 0.097); TAC at discharge was 9.00 [6.80-11.3] vs 8.9 [7.50-10.6] ng/ml (p = NS); LOS was 35.0 vs 24.5 (p = 0.001). We observed no difference in overall survival between the groups. Multivariate analysis identified independently associated factors with TCMR: AIH (OR = 4.76, 95% CI 1.37-16.46; p = 0.014), absence of significant ascites before LTx (OR = 3.15; 95% CI 1.11-8.95, p = 0.024) and 5th day TAC level (OR = 0.85, 95% CI 0.73-0.997, p = 0.045).

Conclusion: T-cell mediated rejection diagnosed clinically and confirmed histologically occurred in 21 patients (11.4 %). Etiology of AIH, absence of ascites and lower TAC were independent risk factors for TCMR. TCMR had no impact on overall survival.

Keywords: deceased donors liver transplantation, diagnosis, outcome, risk factors, T-cell mediated rejection.

Published: February 21, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adamcová-Selčanová S, Skladaný Ľ, Koller T. Prevalence and risk factors of T-cell mediated rejection in patients after liver transplantation from deceased donors: a retrospective study over 10 years. Vnitr Lek. 2020;66(1):e4-10. doi: 10.36290/vnl.2020.026.
Download citation

References

  1. Terminology for hepatic allograft rejection. International Working Party. Hepatology 1995; 22: 648-654. Go to PubMed...
  2. Fisher L, Henley K, Lucey M Acute cellular rejection after liver transplantation: Variability, morbidity and mortality. Liver Transpl Surg 1995; 1: 10-15. Go to original source... Go to PubMed...
  3. Neil DA, Hübscher SG. Current views on rejection pathology in liver transplantation. Transpl Int 2010; 23: 971-983. Go to original source... Go to PubMed...
  4. Sticova E, Honsova E Diagnostika rejekce v transplantovaných játrech. Cesk Patol 2015; 51: 166-168. Go to PubMed...
  5. Deschenes M, Belle SH, Krom RA, et al. Early allograft dysfunction after liver transplantation: a definition and predictors of outcome. National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transplantation 1998; 15: 302-310. Go to original source... Go to PubMed...
  6. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007; 69: 545-556. Go to original source... Go to PubMed...
  7. Stefanova I, Dorfman JR, Tsukamoto M, et al. On the role of self-recognition in T cell responses to foreign antigen. Immunol Rev 2003; 191: 97-106. Go to original source... Go to PubMed...
  8. Afzali B, Lombardi G, Lechler RI Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13: 438-444. Go to original source... Go to PubMed...
  9. Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: Introduction of antibody-mediated rejection. Am J Transplant 2016; 16: 2816-2835. Go to original source... Go to PubMed...
  10. Banff Working Group on Liver Allograft Pathology. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663. Go to original source... Go to PubMed...
  11. Goddard S, Adams DH Methylprednisolone therapy for acute rejection: too much of a good thing? Liver Transpl 2002; 8: 535. Go to original source... Go to PubMed...
  12. Volpin R, Angeli P, Galioto A, et al. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl 2002; 8: 527. Go to original source... Go to PubMed...
  13. Wiesner RH, Menon KV. Late hepatic allograft dysfunction. Liver Transpl 2001; 7: 60. Go to original source... Go to PubMed...
  14. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit anti-thymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396-1399. Go to original source... Go to PubMed...
  15. Lee JG, Lee J, Lee JJ, et al. Efficacy of rabbit anti-thymocyte globulin for steroid-resistant acute rejection after liver transplantation. Medicine (Baltimore) 2016; 95: 3711. Go to original source... Go to PubMed...
  16. Aydogan C, Sevmis S, Aktas S, et al. Steroidresistant acute rejections after liver transplant. Exp Clin Transplant 2010; 8: 172-177.
  17. Lu XJ, Chen YH, Ma Y, et al. Strategies in clinical diagnosis and treatment of steroid-resistant acute rejection after orthotopic liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2016; 24: 297-301. Go to PubMed...
  18. Bonnefoy-Berard N, Revillard JP Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15: 435-442.
  19. Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 2005; 79: 12-16. Go to original source... Go to PubMed...
  20. Koch M, Niemeyer G, Patel I, et al. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002; 73: 1640. Go to original source... Go to PubMed...
  21. Fernandes ML, Lee YM, Sutedja D, et al. Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005; 37: 2179. Go to original source... Go to PubMed...
  22. Haddad EM, McAlister VC, Renouf E, et al. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 4: CD005161. Go to original source... Go to PubMed...
  23. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638-645. Go to original source... Go to PubMed...
  24. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998; 29: 143. Go to original source... Go to PubMed...
  25. Gomez-Manero N, Herrero JI, Quiroga J, et al. Prognostic model for early acute rejection after liver transplantation. Liver Transpl 2001; 7: 246-254. Go to original source... Go to PubMed...
  26. Rodríguez-Perálvarez M, García-Caparrós C, Tsochatzis E, et al. Lack of agreement for defining 'clinical suspicion of rejection' in liver transplantation: a model to select candidates for liver biopsy. Transpl Int 2015; 28: 455-464. Go to original source... Go to PubMed...
  27. Sánchez-Fueyo A, Strom TB Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140: 51-64. Go to original source... Go to PubMed...
  28. Germani G, Rodriguez-Castro K, Russo FP, el al. Markers of acute rejection and graft acceptance in liver transplantation. World J Gastroenterol 2015; 21: 1061-1068. Go to original source... Go to PubMed...
  29. Bathgate AJ, Hynd P, Sommerville D, et al. The prediction of acute cellular rejection in orthotopic liver transplantation. Liver Transpl Surg 1999; 5: 475. Go to original source... Go to PubMed...
  30. Bartlett AS, Ramadas R, Furness S, et al. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002; 8: 1147. Go to original source... Go to PubMed...
  31. Choudhary NS, Saigal S, Saraf N, et al. Acute and chronic rejection after liver transplantation: what a clinician needs to know. Journal of Clinical and Experimental Hepatology 2017; 7: 358-366. Go to original source... Go to PubMed...
  32. Ramirez CB, Marino IR The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 2007; 7: 137-148. Go to original source... Go to PubMed...
  33. Ramirez CB, Doria C, di Francesco F, et al. Anti-IL2 induction in liver transplantation with 93% rejection free patient and graft survival at 18 months. J Surg Res 2007; 138: 198. Go to original source... Go to PubMed...
  34. Gruttadauria S, Vasta F, Mandalà L, et al. Basiliximab in a triple-drug regimen with tacrolimu and steroids in liver transplantation. Transplant Proc 2005; 37: 2611. Go to original source... Go to PubMed...
  35. Raimondo ML, Burroughs AK. Single-agent immunosuppression after liver transplantation: what is possible? Drugs 2002; 62: 1587-1597. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.